A Phase 3 interventional study of Apremilast and Placebo in Behçet's Syndrome, sponsored by Amgen. Completed at 63 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-22.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main objective of this study is to evaluate the efficacy and safety of apremilast in the treatment of oral ulcers in adults with active Behçet's disease (BD).
Behçet's disease, is a rare disorder that causes inflammation in blood vessels throughout the body. The signs and symptoms of Behçet's disease may include mouth sores, eye inflammation, skin rashes and lesions, and genital sores that vary from person to person and may come and go on their own. The exact cause of Behçet's is unknown, but it may be an autoimmune disorder, which means the body's immune system mistakenly attacks some of its own healthy cells.
This study will evaluate if apremilast is better than placebo (inactive substance in the same form as the drug) for the treatment of oral ulcers in subjects with active Behçet's disease. Other manifestations of the disease will also be assessed, such as, pain and tenderness in joints, eye inflammation, genital ulcers, and skin disease. This study also will test how well the body tolerates apremilast. In addition, the second purpose of the study is to assess the safety of apremilast in patients with Behçet's disease.
This study is a randomized, placebo-controlled, parallel design. The placebo-controlled period will be 12 weeks long and participants will receive apremilast or placebo. After the 12-week placebo-controlled period, all participants will receive apremilast for 52 weeks in the active treatment period. All participants will have their final study visit 4 weeks after stopping apremilast treatment.
Participants in Germany will have the opportunity to enter an optional open-label extension phase after the 52-week active treatment phase (week 64 visit), and continue until apremilast is commercially available for Behçet's disease or until apremilast is found not to be acceptable for Behçet's disease, according to either the sponsor or health authority.
136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.
This study's enrollment of 207 is above the median of 50 across 70 interventional studies indexed under Behcet Syndrome.
Browse Behcet Syndrome studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Subjects must have at least 2 oral ulcers at Visit 1 (Screening Visit), and:
Candidate for systemic therapy, for the treatment of oral ulcers.
a. A candidate for systemic therapy is a subject judged by the study Investigator as someone whose mucocutaneous ulcers are considered inappropriate for topical therapy based on the severity of disease and extent of the affected area, or whose oral ulcers cannot be adequately controlled by topical therapy.
Laboratory Measures: Must meet the following laboratory measures:
Laboratory tests will be allowed to be repeated 1 time if, in the Investigator's clinical judgment, there is a reasonable possibility of the repeat tests not meeting the exclusion values, and with concurrence from the Medical Monitor.
Requirements:
All Females of Child Bearing Potential (FCBP) must use one of the approved contraceptive options as described below while taking apremilast and for at least 28 days after administration of the last dose of the apremilast.
At the time of study entry, and at any time during the study when a FCBP's contraceptive measures or ability to become pregnant changes, the Investigator will educate the subject regarding contraception options and the correct and consistent use of effective contraceptive methods in order to successfully prevent pregnancy.
All FCBP must have a negative pregnancy test at Visits 1 and 2. All FCBP subjects who engage in activity in which conception is possible must use one of the approved contraceptive options described below:
Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom (latex condom or non-latex condom NOT made out of natural [animal] membrane [for example, polyurethane]); PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (latex or non-latex condoms NOT made out of natural [animal] membrane [for example, polyurethane]) while on IP and for at least 28 days after the last dose of IP.
Exclusion Criteria: The presence of any of the following will exclude a subject from the study enrollment.
Disease Specific Exclusions:
Behçet's disease-related active major organ involvement - pulmonary (eg, pulmonary artery aneurysm), vascular (eg, thrombophlebitis), gastrointestinal (eg, ulcers along the gastrointestinal tract), and central nervous systems (eg, meningoencephalitis) manifestations, and ocular lesions (eg, uveitis) requiring therapy; however:
Having received concomitant immune modulating therapy (except oral or topical corticosteroids) within:
Note: Oral and topical corticosteroids must have been tapered as appropriate and discontinued prior to the day of Visit 2 (day of randomization).
or history of malignancy, except for:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this arm will receive placebo tablets twice daily by mouth for the first twelve weeks followed by 52 weeks of 30 mg apremilast tablets twice daily by mouth.
Drug: Apremilast · Drug: Placebo
Participants randomized to this arm will receive 30 mg apremilast tablets twice daily by mouth for 64 weeks.
Drug: Apremilast
Tablets for oral administration
Also known as: Otezla®, CC-10004
Tablets for oral administration
Area Under the Curve (AUC) for the Number of Oral Ulcers From Baseline Through Week 12 (AUC W0-12)
The number of oral ulcers that was counted for the analysis of the primary endpoint included current and recurrent ulcers at each time point; a single oral ulcer could be recounted multiple times if it persisted or recurred at subsequent visits.
Time frame: Oral ulcers were assessed at weeks 0 (baseline), 1, 2, 4, 6, 8, 10, and 12 during the placebo-controlled period.
Change From Baseline in Oral Ulcer Pain as Measured by Visual Analog Scale (VAS) at Week 12
Pain of oral ulcers was measured using a 100 mm VAS scale. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was recorded. A negative change from baseline indicates improvement.
Time frame: Baseline to week 12
Change From Baseline in Disease Activity as Measured by Behçet's Syndrome Activity Score (BSAS) at Week 12
The Behçet's Syndrome Activity Score (BSAS) contains 10 questions that assess the number of new oral and genital ulcers and skin lesions, GI, CNS, vascular, and ocular involvement, and the participant's current level of discomfort. The Behçet's Syndrome Activity Score ranges from 0 to 100, with a higher score indicating a higher level of disease activity. A negative change from baseline indicates improvement.
Time frame: Baseline to week 12
Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Behçet's Disease Current Activity Index (BDCAI) at Week 12
The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's Disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The BDCAI consists of 12 questions regarding disease manifestations over the previous 4 weeks, including oral and genital disease activity, as well as other manifestations of BD involving the skin, joints, GI tract, eyes, nervous system, and vascular system. The BDCAI score is the sum score of 12 items and ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening), and a negative change from baseline indicates improvement.
Time frame: Baseline to week 12
Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Patient's Perception of Disease Activity at Week 12
The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's Disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The Patient's Perception of Disease Activity was assessed on a scale from 1 to 7, where a higher score indicates a higher level of disease activity and a negative change from baseline indicates improvement.
Time frame: Baseline to week 12
Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Clinician's Overall Perception of Disease Activity at Week 12
The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The Clinician's Overall Perception of Disease Activity was assessed on a scale from 1 to 7, where a higher score indicates a higher level of disease activity and a negative change from baseline indicates improvement.
Time frame: Baseline to week 12
Percentage of Participants Who Achieved an Oral Ulcer Complete Response (Oral Ulcer-Free) by Week 6 and Remained Oral Ulcer-Free for at Least 6 Additional Weeks
Participants who were oral ulcer-free by week 6 and remained oral ulcer-free for at least 6 consecutive weeks during the 12-week placebo-controlled treatment phase.
Time frame: Baseline to week 12
Time to Oral Ulcer Resolution (Complete Response)
Time to oral ulcer resolution (defined as oral ulcer-free) was the time between the first dose date and the date when a complete response was achieved for the first time during the placebo-controlled treatment phase. For participants who did not achieve complete response or discontinued treatment before a complete response was achieved during the placebo-controlled treatment phase, time to event was censored at the last oral ulcer assessment date during the placebo-controlled treatment phase or the first dose date if there were no postbaseline ulcer assessments. Median and 95% confidence interval was based on Kaplan-Meier estimates.
Time frame: Baseline to week 12
Percentage of Participants Who Experienced an Oral Ulcer Complete Response at Week 12
A complete response at week 12 was defined as participants who were oral ulcer free at week 12.
Time frame: Week 12
Change From Baseline in Behçet's Disease Quality of Life (BD Qol) Scores at Week 12
The Behçet's Disease Quality of Life questionnaire was developed to measure the influence of BD on a particpant's life. It consists of 30 self-completed itemized questions that measure disease-related restrictions on the participant's activities and their emotional response to these restrictions. The total score is the sum of all 30 items (each yes scores 1 and each no scores 0), with 0 representing no influence of Behçet's disease on a participant's quality of life and 30 representing the most severe influence. A negative change from baseline indicates improvement.
Time frame: Baseline to week 12
Percentage of Participants Who Experienced a Complete Response For Genital Ulcers at Week 12
A genital ulcer complete response at week 12 was defined as participants who were genital ulcer-free at week 12.
Time frame: Week 12
Percentage of Participants With no Oral Ulcers Following a Complete Response
The definition includes participants who remained oral ulcer-free through week 12 after achieving a complete response (oral ulcer-free) prior to week 12.
Time frame: Baseline to week 12
Time to Recurrence of Oral Ulcers Following Loss of Complete Response
Time to recurrence of oral ulcers following the loss of complete response (oral ulcer-free) was defined as the first instance when a participant had a reappearance of oral ulcers following a complete response, during the placebo-controlled treatment phase. For participants who did not have oral ulcer recurrence or discontinued treatment before any oral ulcer recurrence during the placebo-controlled treatment phase, time to event was censored at the last oral ulcer assessment during placebo-controlled treatment phase; For participants without any oral ulcer assessment following the first complete response, time to event was censored to the first complete response date.
Time frame: Baseline through week 12
Number of Oral Ulcers Following Loss of Complete Response Through Week 12
Number of oral ulcers reported at the time of the first loss of complete response, ie, at the first instance when a participant had a reappearance of oral ulcers following a complete response, during the placebo-controlled treatment phase.
Time frame: Baseline to week 12
Change From Baseline in the Total Score of the Static Physician's Global Assessment (PGA) of Skin Lesions of BD at Week 12
BD-related skin lesions (including acne-like lesions, folliculitis, and erythema nodosum) were evaluated according to the Static Physician's Global Assessment as follows: Score 0 = clear skin. Score 1 = mild in severity with the presence of 1 to 10 lesions (papules, pustules, cysts) or nodules at any anatomical site. Score 2 = Moderate severity; presence of 11 to 20 nodules or lesions (papules, pustules, cysts) at any anatomical site. Score 3 = Severe; presence of \> 20 nodules or lesions (papules, pustules, cysts) at any anatomical site. The total sore was calculated as the sum of the acne-like lesions, folliculitis, and erythema nodosum scores, and therefore ranges from 0 to 9, where a higher score indicates a higher level of activity. A negative change from baseline indicates improvement.
Time frame: Baseline to week 12
Change From Baseline in Genital Ulcer Pain as Measured by VAS Score at Week 12
Pain of genital ulcers was measured using a 100 mm visual analog scale. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was recorded. A negative change from baseline indicates improvement.
Time frame: Baseline to week 12
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo-controlled Treatment Period
A TEAE is an adverse event (AE) with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. A serious AE (SAE) is any AE that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or constituted an important medical event. For both AEs and SAEs the investigator assessed the severity of the event according to the grading scale: Mild: asymptomatic or with mild symptoms; Moderate: symptoms causing moderate discomfort and local or noninvasive intervention is indicated; Severe: symptoms causing severe discomfort or pain, symptoms requiring medical/surgical intervention.
Time frame: From first dose of study drug in the placebo-controlled phase to the first dose of apremilast in the active treatment phase (12 weeks) or up to 28 days after last dose for participants who did not receive study drug at week 12, whichever was earlier.
Number of Participants With TEAEs During the Apremilast-Exposure Period
The apremilast-exposure period started on the date of the first dose of apremilast (week 0 for participants assigned to apremilast or week 12 for participants who were originally assigned to placebo and switched to apremilast at week 12) and ended 28 days after last dose in the active treatment phase. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. An SAE is any AE that resulted in death; was life-threatening; required or prolonged inpatient hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or constituted an important medical event. The investigator assessed the severity of each event according to the grading scale: Mild: asymptomatic or mild symptoms; Moderate: symptoms causing moderate discomfort, local or noninvasive intervention indicated; Severe: symptoms causing severe discomfort or pain, requiring medical/surgical intervention.
Time frame: From first dose of apremilast (week 0 for those assigned to apremilast or week 12 for those assigned to placebo) up to 28 days after last dose; up to 56 weeks and 68 weeks in each arm respectively.
The study was conducted at 53 sites in Europe (France, Germany, Greece, and Italy), Asia (Japan and the Republic of Korea), the United States, and Rest of the World (Israel, Lebanon, and Turkey).
| Milestone | Placebo/Apremilast | Apremilast |
|---|---|---|
| Started | 103 | 104 |
| Completed | 83 | 96 |
| Not completed | 20 | 8 |
| Withdrew: Adverse event | 4 | 3 |
| Withdrew: Lack of efficacy | 8 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Milestone | Placebo/Apremilast | Apremilast |
|---|---|---|
| Started | 83 | 95 |
| Completed | 68 | 75 |
| Not completed | 15 | 20 |
| Withdrew: Miscellaneous | 0 | 1 |
| Withdrew: Adverse event | 4 | 9 |
| Withdrew: Lack of efficacy | 2 | 2 |
| Withdrew: Withdrawal by subject | 7 | 7 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Pregnancy | 1 | 0 |
| Milestone | Placebo/Apremilast | Apremilast |
|---|---|---|
| Started | 2 | 0 |
| Completed | 1 | 0 |
| Not completed | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
The number of oral ulcers that was counted for the analysis of the primary endpoint included current and recurrent ulcers at each time point; a single oral ulcer could be recounted multiple times if it persisted or recurred at subsequent visits.
| Ulcers*days | Placebo | Apremilast 30 mg BID |
|---|---|---|
| Area Under the Curve (AUC) for the Number of Oral Ulcers From Baseline Through Week 12 (AUC W0-12) | 222.14 ± 15.886 | 129.54 ± 15.943 |
Pain of oral ulcers was measured using a 100 mm VAS scale. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was recorded. A negative change from baseline indicates improvement.
| mm | Placebo | Apremilast 30 mg BID |
|---|---|---|
| Change From Baseline in Oral Ulcer Pain as Measured by Visual Analog Scale (VAS) at Week 12 | -15.9 ± 3.31 | -40.7 ± 3.34 |
The Behçet's Syndrome Activity Score (BSAS) contains 10 questions that assess the number of new oral and genital ulcers and skin lesions, GI, CNS, vascular, and ocular involvement, and the participant's current level of discomfort. The Behçet's Syndrome Activity Score ranges from 0 to 100, with a higher score indicating a higher level of disease activity. A negative change from baseline indicates improvement.
| Units on a scale | Placebo | Apremilast 30 mg BID |
|---|---|---|
| Change From Baseline in Disease Activity as Measured by Behçet's Syndrome Activity Score (BSAS) at Week 12 | -5.41 ± 1.776 | -17.35 ± 1.796 |
The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's Disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The BDCAI consists of 12 questions regarding disease manifestations over the previous 4 weeks, including oral and genital disease activity, as well as other manifestations of BD involving the skin, joints, GI tract, eyes, nervous system, and vascular system. The BDCAI score is the sum score of 12 items and ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening), and a negative change from baseline indicates improvement.
| Units on a scale | Placebo | Apremilast 30 mg BID |
|---|---|---|
| Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Behçet's Disease Current Activity Index (BDCAI) at Week 12 | -0.4 ± 0.20 | -0.9 ± 0.20 |
The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's Disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The Patient's Perception of Disease Activity was assessed on a scale from 1 to 7, where a higher score indicates a higher level of disease activity and a negative change from baseline indicates improvement.
| Units on a scale | Placebo | Apremilast 30 mg BID |
|---|---|---|
| Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Patient's Perception of Disease Activity at Week 12 | -0.7 ± 0.18 | -1.7 ± 0.18 |
The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The Clinician's Overall Perception of Disease Activity was assessed on a scale from 1 to 7, where a higher score indicates a higher level of disease activity and a negative change from baseline indicates improvement.
| Units on a scale | Placebo | Apremilast 30 mg BID |
|---|---|---|
| Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Clinician's Overall Perception of Disease Activity at Week 12 | -0.7 ± 0.17 | -1.6 ± 0.17 |
Participants who were oral ulcer-free by week 6 and remained oral ulcer-free for at least 6 consecutive weeks during the 12-week placebo-controlled treatment phase.
| Percentage of participants | Placebo | Apremilast 30 mg BID |
|---|---|---|
| Percentage of Participants Who Achieved an Oral Ulcer Complete Response (Oral Ulcer-Free) by Week 6 and Remained Oral Ulcer-Free for at Least 6 Additional Weeks | 4.9 | 29.8 |
Time to oral ulcer resolution (defined as oral ulcer-free) was the time between the first dose date and the date when a complete response was achieved for the first time during the placebo-controlled treatment phase. For participants who did not achieve complete response or discontinued treatment before a complete response was achieved during the placebo-controlled treatment phase, time to event was censored at the last oral ulcer assessment date during the placebo-controlled treatment phase or the first dose date if there were no postbaseline ulcer assessments. Median and 95% confidence interval was based on Kaplan-Meier estimates.
| Weeks | Placebo | Apremilast 30 mg BID |
|---|---|---|
| Time to Oral Ulcer Resolution (Complete Response) | 8.1 (4.7 to NA) | 2.1 (2.0 to 4.0) |
A complete response at week 12 was defined as participants who were oral ulcer free at week 12.
| Percentage of participants | Placebo | Apremilast 30 mg BID |
|---|---|---|
| Percentage of Participants Who Experienced an Oral Ulcer Complete Response at Week 12 | 22.3 | 52.9 |
The Behçet's Disease Quality of Life questionnaire was developed to measure the influence of BD on a particpant's life. It consists of 30 self-completed itemized questions that measure disease-related restrictions on the participant's activities and their emotional response to these restrictions. The total score is the sum of all 30 items (each yes scores 1 and each no scores 0), with 0 representing no influence of Behçet's disease on a participant's quality of life and 30 representing the most severe influence. A negative change from baseline indicates improvement.
| Units on a scale | Placebo | Apremilast 30 mg BID |
|---|---|---|
| Change From Baseline in Behçet's Disease Quality of Life (BD Qol) Scores at Week 12 | -0.5 ± 0.66 | -3.5 ± 0.67 |
A genital ulcer complete response at week 12 was defined as participants who were genital ulcer-free at week 12.
| Percentage of participants | Placebo | Apremilast 30 mg BID |
|---|---|---|
| Percentage of Participants Who Experienced a Complete Response For Genital Ulcers at Week 12 | 41.2 | 70.6 |
The definition includes participants who remained oral ulcer-free through week 12 after achieving a complete response (oral ulcer-free) prior to week 12.
| Percentage of participants | Placebo | Apremilast 30 mg BID |
|---|---|---|
| Percentage of Participants With no Oral Ulcers Following a Complete Response | 13.2 | 31.3 |
Time to recurrence of oral ulcers following the loss of complete response (oral ulcer-free) was defined as the first instance when a participant had a reappearance of oral ulcers following a complete response, during the placebo-controlled treatment phase. For participants who did not have oral ulcer recurrence or discontinued treatment before any oral ulcer recurrence during the placebo-controlled treatment phase, time to event was censored at the last oral ulcer assessment during placebo-controlled treatment phase; For participants without any oral ulcer assessment following the first complete response, time to event was censored to the first complete response date.
| Weeks | Placebo | Apremilast 30 mg BID |
|---|---|---|
| Time to Recurrence of Oral Ulcers Following Loss of Complete Response | 2.3 (2.1 to 4.1) | 4.6 (3.1 to 6.1) |
Number of oral ulcers reported at the time of the first loss of complete response, ie, at the first instance when a participant had a reappearance of oral ulcers following a complete response, during the placebo-controlled treatment phase.
| oral ulcers | Placebo | Apremilast 30 mg BID |
|---|---|---|
| Number of Oral Ulcers Following Loss of Complete Response Through Week 12 | 1.5 ± 0.21 | 1.1 ± 0.18 |
BD-related skin lesions (including acne-like lesions, folliculitis, and erythema nodosum) were evaluated according to the Static Physician's Global Assessment as follows: Score 0 = clear skin. Score 1 = mild in severity with the presence of 1 to 10 lesions (papules, pustules, cysts) or nodules at any anatomical site. Score 2 = Moderate severity; presence of 11 to 20 nodules or lesions (papules, pustules, cysts) at any anatomical site. Score 3 = Severe; presence of \> 20 nodules or lesions (papules, pustules, cysts) at any anatomical site. The total sore was calculated as the sum of the acne-like lesions, folliculitis, and erythema nodosum scores, and therefore ranges from 0 to 9, where a higher score indicates a higher level of activity. A negative change from baseline indicates improvement.
| scores on a scale | Placebo | Apremilast 30 mg BID |
|---|---|---|
| Change From Baseline in the Total Score of the Static Physician's Global Assessment (PGA) of Skin Lesions of BD at Week 12 | -0.8 ± 0.14 | -0.9 ± 0.14 |
Pain of genital ulcers was measured using a 100 mm visual analog scale. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was recorded. A negative change from baseline indicates improvement.
| mm | Placebo | Apremilast 30 mg BID |
|---|---|---|
| Change From Baseline in Genital Ulcer Pain as Measured by VAS Score at Week 12 | -24.5 ± 10.75 | -30.0 ± 11.22 |
A TEAE is an adverse event (AE) with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. A serious AE (SAE) is any AE that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or constituted an important medical event. For both AEs and SAEs the investigator assessed the severity of the event according to the grading scale: Mild: asymptomatic or with mild symptoms; Moderate: symptoms causing moderate discomfort and local or noninvasive intervention is indicated; Severe: symptoms causing severe discomfort or pain, symptoms requiring medical/surgical intervention.
| Participants | Placebo | Apremilast 30 mg BID |
|---|---|---|
| Any TEAE | 74 | 82 |
| Any Drug-related TEAE | 37 | 60 |
| Any Severe TEAE | 6 | 6 |
| Any Serious TEAE | 4 | 3 |
| Any TEAE Leading to Drug Interruption | 6 | 9 |
| Any TEAE Leading to Drug Withdrawal | 5 | 3 |
| Any TEAE Leading to Death | 0 | 0 |
The apremilast-exposure period started on the date of the first dose of apremilast (week 0 for participants assigned to apremilast or week 12 for participants who were originally assigned to placebo and switched to apremilast at week 12) and ended 28 days after last dose in the active treatment phase. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. An SAE is any AE that resulted in death; was life-threatening; required or prolonged inpatient hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or constituted an important medical event. The investigator assessed the severity of each event according to the grading scale: Mild: asymptomatic or mild symptoms; Moderate: symptoms causing moderate discomfort, local or noninvasive intervention indicated; Severe: symptoms causing severe discomfort or pain, requiring medical/surgical intervention.
| Participants | Placebo/Apremilast | Apremilast/Apremilast |
|---|---|---|
| Any TEAE | 70 | 90 |
| Any Drug-related TEAE | 29 | 64 |
| Any Severe TEAE | 4 | 17 |
| Any Serious TEAE | 7 | 10 |
| Any TEAE Leading to Drug Interruption | 10 | 17 |
| Any TEAE Leading to Drug Withdrawal | 3 | 12 |
| Any TEAE Leading to Death | 0 | 0 |
Collected over Placebo-controlled phase: From first dose of study drug to week 12 or up to 28 days after last dose for participants who did not receive study drug at week 12. Apremilast Exposure Phase: From first dose of apremilast (week 0 or week 12 for those assigned to placebo) up to 28 days after last dose; up to 56 weeks and 68 weeks in each arm respectively. Open-label extension: From first dose of apremilast in the extension phase to 28 days after last dose, up to 784 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-controlled Phase: Placebo | 0/103 (0%) | 4/103 (3.9%) | 52/103 (50.5%) |
| Placebo-controlled Phase: Apremilast 30 mg BID | 0/104 (0%) | 3/104 (2.9%) | 67/104 (64.4%) |
| Apremilast Exposure Period: Apremilast 30 mg BID | 0/187 (0%) | 17/187 (9.1%) | 132/187 (70.6%) |
| Open-label Extension Phase: Apremilast 30 mg BID | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg BID | Apremilast Exposure Period: Apremilast 30 mg BID | Open-label Extension Phase: Apremilast 30 mg BID |
|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/103 | 0/104 | 2/187 | 0/2 |
| Behcet's syndromeVascular disorders | 0/103 | 1/104 | 2/187 | 0/2 |
| Mouth ulcerationGastrointestinal disorders | 1/103 | 0/104 | 0/187 | 0/2 |
| Diarrhoea infectiousInfections and infestations | 1/103 | 0/104 | 0/187 | 0/2 |
| Genital infectionInfections and infestations | 1/103 | 0/104 | 0/187 | 0/2 |
| Genital infection fungalInfections and infestations | 1/103 | 0/104 | 0/187 | 0/2 |
| Acute febrile neutrophilic dermatosisSkin and subcutaneous tissue disorders | 1/103 | 0/104 | 0/187 | 0/2 |
| Erythema multiformeSkin and subcutaneous tissue disorders | 1/103 | 0/104 | 0/187 | 0/2 |
| Skin lesionSkin and subcutaneous tissue disorders | 1/103 | 0/104 | 0/187 | 0/2 |
| Soft tissue injuryInjury, poisoning and procedural complications | 0/103 | 1/104 | 1/187 | 0/2 |
| Event | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg BID | Apremilast Exposure Period: Apremilast 30 mg BID | Open-label Extension Phase: Apremilast 30 mg BID |
|---|---|---|---|---|
| DepressionPsychiatric disorders | 1/103 | 0/104 | 1/187 | 2/2 |
| Dry eyeEye disorders | 1/103 | 0/104 | 0/187 | 1/2 |
| ConstipationGastrointestinal disorders | 3/103 | 0/104 | 3/187 | 1/2 |
| DiarrhoeaGastrointestinal disorders | 21/103 | 43/104 | 74/187 | 1/2 |
| Impaired gastric emptyingGastrointestinal disorders | 0/103 | 0/104 | 0/187 | 1/2 |
| NauseaGastrointestinal disorders | 11/103 | 20/104 | 36/187 | 1/2 |
| Eye infectionInfections and infestations | 0/103 | 0/104 | 0/187 | 1/2 |
| Helicobacter infectionInfections and infestations | 0/103 | 0/104 | 0/187 | 1/2 |
| Urinary tract infectionInfections and infestations | 4/103 | 1/104 | 2/187 | 1/2 |
| Bone contusionInjury, poisoning and procedural complications | 0/103 | 0/104 | 0/187 | 1/2 |
The intent to treat (ITT) population was defined as all randomized participants who received at least 1 dose of investigational product (IP). Participants were included in the treatment group to which they were originally randomized.
| Age, Continuous(Years) | Placebo | Apremilast 30 mg BID | Total |
|---|---|---|---|
| Mean | 40.6 ± 12.66 | 39.4 ± 12.12 | 40.0 ± 12.37 |
| Sex: Female, Male(Participants) | Placebo | Apremilast 30 mg BID | Total |
|---|---|---|---|
| Female | 63 | 64 | 127 |
| Male | 40 | 40 | 80 |
| Race (NIH/OMB)(Participants) | Placebo | Apremilast 30 mg BID | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 30 | 32 | 62 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 0 | 1 | 1 |
| White | 68 | 69 | 137 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Region of the World(Participants) | Placebo | Apremilast 30 mg BID | Total |
|---|---|---|---|
| Europe | 27 | 25 | 52 |
| North America | 11 | 14 | 25 |
| Asia | 29 | 32 | 61 |
| Rest of World | 36 | 33 | 69 |
| Duration of Behcet's Disease(Years) | Placebo | Apremilast 30 mg BID | Total |
|---|---|---|---|
| Mean | 6.94 ± 7.966 | 6.74 ± 7.397 | 6.84 ± 7.667 |
| Oral Ulcer Count(Oral ulcers) | Placebo | Apremilast 30 mg BID | Total |
|---|---|---|---|
| Mean | 3.9 ± 2.70 | 4.2 ± 3.65 | 4.1 ± 3.21 |
| Pain of Oral Ulcers Visual Analog Scale (VAS)(mm) | Placebo | Apremilast 30 mg BID | Total |
|---|---|---|---|
| Mean | 60.8 ± 26.92 | 61.2 ± 27.55 | 61.0 ± 27.17 |
| Behçet's Disease Current Activity Index (BDCAI) Score(Units on a scale) | Placebo | Apremilast 30 mg BID | Total |
|---|---|---|---|
| Mean | 3.6 ± 1.67 | 3.7 ± 1.58 | 3.7 ± 1.62 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Dec 2014 to primary completion in Sep 2017, 32 months.
Results were first posted in Sep 2019, 1 year 11 months after primary completion. A results delay was requested in Jan 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast